← Back to All US Stocks

DBD Stock Analysis - DIEBOLD NIXDORF, Inc AI Rating

DBD NYSE Calculating & Accounting Machines (No Electronic Computers) DE CIK: 0000028823
Recently Updated • Analysis: Mar 23, 2026 • SEC Data: 2025-12-31
HOLD
62%
Pending
Analysis scheduled

📊 DBD Key Takeaways

Revenue: $3.8B
Net Margin: 2.5%
Free Cash Flow: $288.5M
Current Ratio: 1.30x
Debt/Equity: 0.85x
EPS: $2.54
AI Rating: HOLD with 62% confidence

Investment Thesis

Claude

Diebold Nixdorf demonstrates solid operational fundamentals with strong free cash flow generation ($288.5M) and reasonable leverage metrics, but faces headwinds from modest revenue growth (+1.5% YoY) and declining net income (-3.0% YoY) despite operational improvements. The company's ability to convert operating cash flow into returns appears constrained by low profitability margins (2.5% net margin) and moderate returns on equity (8.6%), suggesting limited growth momentum in its legacy ATM and banking solutions market.

DBD Strengths

Claude
  • + Strong free cash flow generation at $288.5M with healthy 7.6% FCF margin, enabling debt reduction and shareholder returns
  • + Solid balance sheet with manageable debt-to-equity ratio of 0.85x and adequate interest coverage of 3.2x, indicating financial stability
  • + Operating cash flow of $300.7M significantly exceeds net income, suggesting quality earnings and capital-efficient operations

DBD Risks

Claude
  • ! Anemic revenue growth of 1.5% YoY signals weak market demand and potential headwinds in legacy ATM/banking hardware segment
  • ! Declining net income (-3.0% YoY) despite revenue growth indicates margin compression and operational challenges, offset only by one-time EPS gains
  • ! Low profitability margins (2.5% net, 6.4% operating) and weak returns on equity (8.6%) suggest limited competitive advantages and pricing power in maturing markets

Key Metrics to Watch

DBD Financial Metrics

Revenue
$3.8B
Net Income
$94.6M
EPS (Diluted)
$2.54
Free Cash Flow
$288.5M
Total Assets
$3.9B
Cash Position
$368.9M

💡 AI Analyst Insight

DIEBOLD NIXDORF, Inc presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.

DBD Profitability Ratios

Gross Margin 25.3%
Operating Margin 6.4%
Net Margin 2.5%
ROE 8.6%
ROA 2.5%
FCF Margin 7.6%

DBD vs Technology Sector

How DIEBOLD NIXDORF, Inc compares to Technology sector averages

Net Margin
DBD 2.5%
vs
Sector Avg 18.0%
DBD Sector
ROE
DBD 8.6%
vs
Sector Avg 22.0%
DBD Sector
Current Ratio
DBD 1.3x
vs
Sector Avg 2.5x
DBD Sector
Debt/Equity
DBD 0.9x
vs
Sector Avg 0.5x
DBD Sector

Sector benchmarks are approximate industry averages. Actual sector performance may vary.

DBD Balance Sheet & Liquidity

Current Ratio
1.30x
Quick Ratio
0.92x
Debt/Equity
0.85x
Debt/Assets
71.3%
Interest Coverage
3.15x
Long-term Debt
$938.5M

DBD 5-Year Financial Trend

DBD 5-year financial data: Year 2021: Revenue $4.4B, Net Income -$341.3M, EPS N/A. Year 2022: Revenue $3.9B, Net Income -$269.1M, EPS $-3.47. Year 2023: Revenue $3.9B, Net Income -$78.8M, EPS $-1.01. Year 2024: Revenue $3.8B, Net Income -$581.4M, EPS $-7.36. Year 2025: Revenue $3.8B, Net Income $1.4B, EPS $16.74.
Revenue
Net Income
EPS (right axis)

5-Year Trend Summary: DIEBOLD NIXDORF, Inc's revenue has declined by 14% over the 5-year period, indicating business contraction. The most recent EPS of $16.74 reflects profitable operations.

DBD Growth Metrics (YoY)

Revenue Growth
N/A
Year-over-year
Net Income Growth
N/A
Year-over-year
EPS Growth
N/A
Earnings per share
FCF Margin
7.6%
Free cash flow / Revenue

DBD Quarterly Performance

Quarterly financial performance data for DIEBOLD NIXDORF, Inc including revenue, net income, and earnings per share.
Quarter Revenue Net Income EPS
Q3 2025 $927.1M -$22.1M $-0.59
Q2 2025 $915.2M $300.0K $0.01
Q1 2025 $841.1M -$8.3M $-0.22
Q3 2024 $351.6M -$8.9M $-0.24
Q2 2024 $922.2M $300.0K $0.01
Q1 2024 $858.1M -$14.6M $-0.39
Q3 2023 $351.6M -$26.5M $-0.63
Q2 2023 $851.7M -$199.2M N/A

Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.

DBD Capital Allocation

Operating Cash Flow
$300.7M
Cash generated from operations
Stock Buybacks
$130.7M
Shares repurchased (TTM)
Capital Expenditures
$12.2M
Investment in assets
Dividends
None
No dividend program

DBD SEC Filings

Access official SEC EDGAR filings for DIEBOLD NIXDORF, Inc (CIK: 0000028823)

📋 Recent SEC Filings

Date Form Document Action
Mar 17, 2026 4 xslF345X05/wk-form4_1773784205.xml View →
Mar 9, 2026 4 xslF345X05/wk-form4_1773094854.xml View →
Mar 9, 2026 4 xslF345X05/wk-form4_1773094848.xml View →
Mar 3, 2026 4 xslF345X05/wk-form4_1772579208.xml View →
Mar 3, 2026 4 xslF345X05/wk-form4_1772579203.xml View →

Frequently Asked Questions about DBD

What is the AI rating for DBD?

DIEBOLD NIXDORF, Inc (DBD) has an AI rating of HOLD with 62% confidence, based on fundamental analysis of SEC EDGAR filings.

What are DBD's key strengths?

Strong free cash flow generation at $288.5M with healthy 7.6% FCF margin, enabling debt reduction and shareholder returns. Solid balance sheet with manageable debt-to-equity ratio of 0.85x and adequate interest coverage of 3.2x, indicating financial stability.

What are the risks of investing in DBD?

Anemic revenue growth of 1.5% YoY signals weak market demand and potential headwinds in legacy ATM/banking hardware segment. Declining net income (-3.0% YoY) despite revenue growth indicates margin compression and operational challenges, offset only by one-time EPS gains.

What is DBD's revenue and growth?

DIEBOLD NIXDORF, Inc reported revenue of $3.8B.

Does DBD pay dividends?

DIEBOLD NIXDORF, Inc does not currently pay dividends.

Where can I find DBD SEC filings?

Official SEC filings for DIEBOLD NIXDORF, Inc (CIK: 0000028823) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.

What is DBD's EPS?

DIEBOLD NIXDORF, Inc has a diluted EPS of $2.54.

How is the AI analysis conducted?

Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.

Disclaimer: This analysis is generated by Claude AI based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: Mar 23, 2026 | Data as of: 2025-12-31 | Powered by Claude AI